Cingulate (CING) to Release Earnings on Thursday

Cingulate (NASDAQ:CING) is expected to be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 22, 2026 at 9:30 AM ET.

Cingulate (NASDAQ:CING) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.28). On average, analysts expect Cingulate to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cingulate Trading Down 5.9%

Cingulate stock opened at $4.96 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.16 and a quick ratio of 1.16. The company has a market capitalization of $60.76 million, a price-to-earnings ratio of -1.15 and a beta of -0.81. Cingulate has a one year low of $3.20 and a one year high of $11.89. The company’s fifty day moving average price is $6.38 and its two-hundred day moving average price is $5.27.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Ascendiant Capital Markets lowered their target price on shares of Cingulate from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cingulate in a report on Monday, April 20th. Finally, Roth Mkm lowered their price objective on Cingulate from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $34.50.

Institutional Investors Weigh In On Cingulate

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in Cingulate by 283.1% during the second quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock worth $31,000 after buying an additional 5,543 shares in the last quarter. XTX Topco Ltd acquired a new stake in Cingulate during the second quarter worth $45,000. DRW Securities LLC acquired a new stake in Cingulate during the fourth quarter worth $255,000. Kestra Advisory Services LLC boosted its stake in Cingulate by 29.8% in the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock valued at $529,000 after buying an additional 27,979 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Cingulate by 43.9% in the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock valued at $265,000 after buying an additional 18,629 shares in the last quarter. Institutional investors and hedge funds own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.